Exelixis | EXEL - Trade Creditors


Exelixis reported $39.06M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Akebia Therapeutics USD 9.42M 1.04M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
Bayer EUR 6.39B 192M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Cytokinetics USD 20.51M 4.2M Jun/2026
Eisai JPY 87.53B 11.64B Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Exelixis USD 39.06M 14.91M Jun/2026
Genmab DKK 116M 110M Jun/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
MacroGenics USD 3.44M 845K Jun/2026
Merck USD 3.83B 36M Jun/2026
Moderna USD 167M 6M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sanofi EUR 22.71B 219M Mar/2026
Takeda JPY 446.78B 44.56B Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Xencor USD 12.65M 4.73M Jun/2026